Developing Uricase-PEG 20 for the Treatment of Gout

Welcome to ! We are a private, clinical stage biotechnology company developing uricase-PEG 20 for the treatment of resistant and refractory gout and related indications in which hyperuricemia plays a causative role. Our patented formulation of pegylated uricase is designed to have a long half life as well as reduced immunogenicity.

Gout

Gout is an intermittent inflammatory arthritis caused by the formation of uric acid crystals in joint fluid. Uric acid is an end product of purine nucleotide metabolism; in almost all other animals, the enzyme uricase…

Learn More

Recent News

May 28, 2008
EnzymeRx Announces Receipt of $14 million Capital Investment and Acquisition of Pegylated Uricase

[ MORE ]